Event Sponsored by LIXTE Biotechnology Holdings,Developer of Breakthrough Cancer Therapies Atlanta, GA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Inspired by the music, legacy, and lived experiences of De La Soul, the inaugural Good Health: Mind, Body & Soul Summit will take place February 19 at Morehouse College in Atlanta. This invitation-only event brings together leaders in health, culture, science, and community to advance health equity for Black men and families. It is made possible by the generous sponsorshi ...

BOCA RATON, Fla., Jan. 20, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical-stage pharmaceutical company advancing LB-100, a first-in-class inhibitor of protein phosphatase 2A (PP2A), today announced the Company will participate at the DealFlow Discovery Conference in Atlantic City, New Jersey, January 28-29, 2026. Geordan Pursglove, LIXTE’s Chief Executive Officer, will conduct one-on-one meetings with investors during the conference. The con ...

Core Insights - LIXTE Biotechnology Holdings, Inc. has acquired Liora Technologies Europe Ltd., marking its entry into the radiotherapy segment of cancer care [1][3] - The acquisition includes Liora's LiGHT System, which offers significant advantages in proton therapy for treating tumors [2][3] - The LiGHT System is expected to set a new standard in cancer treatment, providing high-precision therapy that is scalable and clinically versatile [3] Company Overview - LIXTE is a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, with a lead compound, LB-100, that has shown promise in clinical trials [4][5] - The company aims to enhance existing cancer treatments through its innovative approach in cancer biology, specifically in activation lethality [5] Technology and Development - The LiGHT System, installed at STFC's Daresbury Laboratory, will serve as a center of excellence for proton therapy treatment [2] - The technology is designed to reduce installation costs and treatment sessions while increasing patient capacity at treatment centers [3]